<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204941</url>
  </required_header>
  <id_info>
    <org_study_id>EZH-301</org_study_id>
    <nct_id>NCT04204941</nct_id>
  </id_info>
  <brief_title>Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma</brief_title>
  <official_title>A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epizyme, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epizyme, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, placebo-controlled, randomized phase 3 study with phase&#xD;
      1b portion designed to establish a recommended phase 3 dose (RP3D) and to evaluate the&#xD;
      efficacy, PK, and safety of tazemetostat + doxorubicin vs placebo + doxorubicin in subjects&#xD;
      with advanced epithelioid sarcoma (ES). This study will be conducted in 2 parts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The open-label phase 1b portion is designed to evaluate the safety of the combination of&#xD;
      tazemetostat + doxorubicin, as well as to establish the maximum tolerated dose (MTD) and the&#xD;
      RP3D. The phase 3 portion of the clinical trial aims to compare tazemetostat + doxorubicin to&#xD;
      the current front-line standard treatment, single-agent doxorubicin + placebo, when used as&#xD;
      first-line treatment in locally advanced unresectable or metastatic ES.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Phase 1b is open label, phase 3 is not open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>DLT's as determined by Adverse Events following administration of Tazemostat in Combination with Doxorubicin</measure>
    <time_frame>1 Cycle/21 days</time_frame>
    <description>Phase 1b: Evaluate the safety and tolerability of tazmetostat in combination with doxorubicin in subjects with advanced STS and select a dose for further evaluation in phase 3 (the RP3D)&#xD;
Phase 3: Evaluate and compare the PFS by independent review committee in subjects with advanced ES treated with tazmetostat + doxorubicin versus placebo + doxorubicin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Phase 3 Evaluate and compare the PFS by independent review committee in subjects with advanced ES treated with tazemetostat + doxorubicin versus placebo + doxorubicin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Advanced Soft Tissue Sarcoma</condition>
  <condition>Advanced Epithelioid Sarcoma</condition>
  <arm_group>
    <arm_group_label>Tazemetostat + Doxorubicin Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tazemetostat (800 mg) administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond.&#xD;
Doxorubicin 75 mg/m2 IV on day 1 of cycles 1-6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Doxorubicin Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycles 7 and beyond.&#xD;
Doxorubicin 75 mg/m2 IV on day 1 of cycles 1-6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>Tazemetostat/placebo will be administered twice daily..</description>
    <arm_group_label>Tazemetostat + Doxorubicin Arm</arm_group_label>
    <other_name>EPZ-6438</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tazemetostat/placebo will be administered twice daily.</description>
    <arm_group_label>Placebo + Doxorubicin Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin HCl</intervention_name>
    <description>75mg/m2 intravenous injection cycles 1 to 6</description>
    <arm_group_label>Placebo + Doxorubicin Arm</arm_group_label>
    <arm_group_label>Tazemetostat + Doxorubicin Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Subjects must meet ALL the following inclusion criteria to be eligible to enroll in this&#xD;
        study:&#xD;
&#xD;
          1. Have voluntarily agreed to provide written informed consent and demonstrated&#xD;
             willingness and ability to comply with all aspects of the protocol. Study related&#xD;
             activities will not start until written consent is obtained.&#xD;
&#xD;
          2. Phase 1b: 18-65 years old histologically confirmed STS&#xD;
&#xD;
          3. Phase 3: â‰¥18 years old with Epithelioid Sarcoma&#xD;
&#xD;
          4. Have measurable disease&#xD;
&#xD;
          5. Females must not be lactating or pregnant at Screening or Baseline (as documented by a&#xD;
             negative pregnancy test)&#xD;
&#xD;
          6. Because of unknown impact on a developing fetus, females must not be pregnant or&#xD;
             breast feeding and agree to use highly effective contraception during the clinical&#xD;
             trial and for 6 months following the final dose of study&#xD;
&#xD;
          7. Male subjects of child-bearing potential must have had either a successful vasectomy&#xD;
             or practice highly effective contraception and use a condom throughout the study&#xD;
             period and for 3 months after doxorubicin or tazmetostat discontinuation.&#xD;
&#xD;
          8. Subjects diagnosed with human immunodeficiency virus (HIV) are eligible to participate&#xD;
             in the study if their infection is well controlled on anti-retroviral therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects meeting ANY of the following exclusion criteria are NOT eligible to enroll in this&#xD;
        study:&#xD;
&#xD;
          1. Prior exposure to tazemetostat or other inhibitor(s) of enhancer of zeste homologue-2&#xD;
             (EZH2).&#xD;
&#xD;
          2. Prior systemic anticancer therapy.&#xD;
&#xD;
          3. Have any prior history of myeloid malignancies, including myelodysplastic syndrome&#xD;
             (MDS) or acute myeloid leukemia (AML).&#xD;
&#xD;
          4. Have prior history of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic&#xD;
             leukemia (T- LBL/T-ALL).&#xD;
&#xD;
          5. Have participated in another interventional clinical study and received&#xD;
             investigational drug within 30 days or 5 half-lives, whichever is longer, prior to the&#xD;
             planned first dose of study treatment.&#xD;
&#xD;
          6. Have known active central nervous system (CNS) or any leptomeningeal metastasis of&#xD;
             primary extracranial tumor.&#xD;
&#xD;
          7. Subjects taking medications that are known potent cytochrome P450 (CYP)3A4&#xD;
             inducers/inhibitors (including St. John's Wort)&#xD;
&#xD;
          8. Are unwilling to exclude Seville oranges, grapefruit juice, AND grapefruit from the&#xD;
             diet and all foods that contain those fruits from time of enrollment to through the&#xD;
             duration of study participation.&#xD;
&#xD;
          9. Major surgery within 4 weeks before the first dose of study treatment. Subjects must&#xD;
             have recovered from surgery prior to enrollment to this study.&#xD;
&#xD;
         10. Are unable to take oral medication OR have malabsorption syndrome or any other&#xD;
             uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting) that might&#xD;
             impair the bioavailability of study treatment.&#xD;
&#xD;
         11. Have an active infection requiring systemic therapy.&#xD;
&#xD;
         12. Are immunocompromised (ie, has a congenital immunodeficiency).&#xD;
&#xD;
         13. Have known hypersensitivity to any component of tazemetostat or doxorubicin.&#xD;
&#xD;
         14. Have a known active infection with hepatitis B virus (HBV, as measured by positive&#xD;
             hepatitis B surface antigen), hepatitis C virus (HCV, as measured by positive&#xD;
             hepatitis C antibody).&#xD;
&#xD;
         15. Any other major illness that, in the Investigator's judgment, will substantially&#xD;
             increase the risk associated with the subject's participation in this study OR&#xD;
             interfere with their ability to receive study treatment or complete the study.&#xD;
&#xD;
         16. Female subjects who are pregnant or breastfeeding.&#xD;
&#xD;
         17. Subjects who have undergone a solid organ transplant.&#xD;
&#xD;
         18. Subjects housed in an institution by order of the authorities or courts.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director, MD</last_name>
    <phone>617-229-7575</phone>
    <email>clinicaltrials@epizyme.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Warren Chow</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Research Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Chua-Alcala</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Falchook, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Attia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Cote</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Insititute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Demetri, MD</last_name>
    </contact>
    <investigator>
      <last_name>George Demetri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Cote, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rashmin Chugh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Van Tine</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Ingham</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Riedel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lara Davis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atrayee Basu Mallick</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center - Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Burgess, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon and HCA Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Ann McKean, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Loggers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Faculty of Medicine - Royal Victoria Hospital</name>
      <address>
        <city>MontrÃ©al</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Alcindor, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Wu Chen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Jones, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

